Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Motor Activity 55 Breast Neoplasms 30 Neoplasms 25 Lung Neoplasms 8 Colorectal Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Fatigue 6 Colonic Neoplasms 6 Polycystic Ovary Syndrome 5 Pancreatic Neoplasms 5 Obesity 5 Multiple Myeloma 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Follicular 4 Lymphoma 4 Lymphedema 4 Esophageal Neoplasms 4 Brain Neoplasms 4 Stomach Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Peripheral Nervous System Diseases 3 Hematologic Neoplasms 3 Endometrial Neoplasms 3 Skin Neoplasms 2 Sarcopenia 2 Recurrence 2 Rectal Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2

Interventions

sotrovimab 1 ciclesonide 1 cabozantinib 1 anifrolumab 1 Standard of Care 1 Specimen Handling 1 Practice Guidelines as Topic 1 Platinum Compounds 1 Nivolumab 1 Niclosamide 1 Methods 1 Ipilimumab 1 Interviews as Topic 1 Immune Checkpoint Inhibitors 1 High-Intensity Interval Training 1 Exercise 1 Educational Status 1 Early Intervention, Educational 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lupus Erythematosus, Systemic × Exercise × 1 year × Clear all

NCT05478018 2025-09-09

LUPEX

Rigshospitalet, Denmark

Phase NA Completed

Lupus Erythematosus, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡